TearLab (OTCMKTS:TEAR) vs. Orchestra BioMed (NASDAQ:OBIO) Head to Head Survey

Orchestra BioMed (NASDAQ:OBIO) and TearLab (OTCMKTS:TEAR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Analyst Ratings

This is a summary of current ratings for Orchestra BioMed and TearLab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
TearLab	0	0	0	0	N/A

Orchestra BioMed currently has a consensus price target of $17.00, indicating a potential upside of 108.59%. Given Orchestra BioMed’s higher probable upside, research analysts plainly believe Orchestra BioMed is more favorable than TearLab.

Profitability

This table compares Orchestra BioMed and TearLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-2,330.46%	-70.18%	-49.17%
TearLab	N/A	N/A	N/A

Earnings & Valuation

This table compares Orchestra BioMed and TearLab’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	105.68	-$49.12 million	($1.48)	-5.51
TearLab	N/A	N/A	N/A	N/A	N/A

TearLab has lower revenue, but higher earnings than Orchestra BioMed.

Institutional & Insider Ownership

53.6% of Orchestra BioMed shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by insiders. Comparatively, 5.2% of TearLab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Orchestra BioMed beats TearLab on 5 of the 8 factors compared between the two stocks.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

About TearLab

TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.